PITTSBURGH — October 21, 2004 — invivodata® inc., an industry leader in electronic patient self-report solutions for clinical research, today announced that chief science officer Saul Shiffman, Ph.D., presented at the Oct. 19 meeting of the Food and Drug Administration’s (FDA) Advisory Committee for Pharmaceutical Science. The Advisory Committee met to consider actions under the FDA’s Critical Path Initiative, which aims to streamline the new-drug- and medical-device development and approval process, allowing effective new products to get to market faster while minimizing costs.
